<DOC>
	<DOCNO>NCT01006785</DOCNO>
	<brief_summary>The purpose study : - investigate safety clinical efficacy sole therapy DLBS1425 suppress disease- ( tumour ) progression subject advanced/metastatic breast cancer ; - determine minimal effective safe dose DLBS1425 therapy advanced/metastatic breast cancer</brief_summary>
	<brief_title>Efficacy Safety DLBS1425 Subjects With Advanced/Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Subjects diagnose Stage IIIB IV breast cancer fail refuse receive standard chemotherapy Subjects expression ER/PR negative ; positive ER/PR expression fail refuse receive hormonal therapy Either + expression HER2/neu gene ECOG status = 02 At least 1 evaluable measurable metastatic lesion define RECIST criterion Adequate haematological , liver , renal function At least 3 week elapse since prior chemotherapy , radiotherapy , biological/hormonal therapy At least 4 week elapse since surgical biopsy / major surgery Allergic trial product Any disease state , include infection uncontrolled illness could interfere trial participation trial evaluation Concurrent herbal ( alternative ) medicine food supplement suspect effect cancer disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>DLBS 1425</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced/Metastatic ( Stage IIIB/IV ) Breast Cancer</keyword>
</DOC>